T

Tonix Pharmaceuticals Holding Corp
D

TNXP

35.290
USD
0.14
(0.40%)
مغلق
حجم التداول
8,033
الربح لكل سهم
-16
العائد الربحي
-
P/E
0
حجم السوق
259,635,517
أصول ذات صلة
A
AKTX
-0.02000
(-1.69%)
1.16000 USD
A
ATOS
0.01260
(1.51%)
0.84910 USD
E
EYPT
0.06000
(0.62%)
9.70000 USD
R
RMTI
-0.00030
(-0.04%)
0.83000 USD
المزيد
الأخبار المقالات

العنوان: Tonix Pharmaceuticals Holding Corp

القطاع: Healthcare
الصناعة: Biotechnology
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targetingCD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.